loading
Schlusskurs vom Vortag:
$17.45
Offen:
$17.14
24-Stunden-Volumen:
567.95K
Relative Volume:
0.35
Marktkapitalisierung:
$1.44B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.84M
KGV:
-36.20
EPS:
-0.47
Netto-Cashflow:
$-44.23M
1W Leistung:
+1.31%
1M Leistung:
+17.81%
6M Leistung:
+61.14%
1J Leistung:
+94.73%
1-Tages-Spanne:
Value
$16.54
$17.41
1-Wochen-Bereich:
Value
$16.16
$18.90
52-Wochen-Spanne:
Value
$8.65
$18.90

Ars Pharmaceuticals Inc Stock (SPRY) Company Profile

Name
Firmenname
Ars Pharmaceuticals Inc
Name
Telefon
858-771-9307
Name
Adresse
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Name
Mitarbeiter
160
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-13
Name
Neueste SEC-Einreichungen
Name
SPRY's Discussions on Twitter

Vergleichen Sie SPRY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SPRY
Ars Pharmaceuticals Inc
17.02 1.44B 0 -44.84M -44.23M -0.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.82 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.35 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
555.67 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
246.00 28.51B 3.81B -644.79M -669.77M -6.24

Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-07 Eingeleitet Scotiabank Sector Outperform
2025-02-10 Eingeleitet Oppenheimer Outperform
2024-08-20 Eingeleitet Cantor Fitzgerald Overweight
2024-08-13 Hochstufung Raymond James Outperform → Strong Buy
2024-08-12 Bestätigt Leerink Partners Outperform
2024-07-25 Eingeleitet Raymond James Outperform
2024-03-05 Hochstufung Leerink Partners Market Perform → Outperform
2024-02-20 Hochstufung William Blair Mkt Perform → Outperform
2023-09-20 Herabstufung William Blair Outperform → Mkt Perform
2023-01-31 Eingeleitet Wedbush Outperform
2023-01-03 Eingeleitet William Blair Outperform
2022-12-13 Eingeleitet SVB Leerink Outperform
Alle ansehen

Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten

pulisher
Jun 18, 2025

Learn to Evaluate (SPRY) using the Charts - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 18, 2025

ARS Pharmaceuticals | 6/18/25 - ktnv.com

Jun 18, 2025
pulisher
Jun 17, 2025

Asthma Market to Expand Significantly by 2034, States - openPR.com

Jun 17, 2025
pulisher
Jun 17, 2025

Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech - Barchart.com

Jun 17, 2025
pulisher
Jun 15, 2025

ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN

Jun 15, 2025
pulisher
Jun 15, 2025

Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier” - Insider Monkey

Jun 15, 2025
pulisher
Jun 12, 2025

Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey

Jun 12, 2025
pulisher
Jun 09, 2025

ARS Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily

Jun 09, 2025
pulisher
Jun 06, 2025

Long Term Trading Analysis for (SPRY) - news.stocktradersdaily.com

Jun 06, 2025
pulisher
Jun 05, 2025

Bank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

ARS Pharmaceuticals - WBFF

Jun 04, 2025
pulisher
Jun 03, 2025

Ameriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

BNP Paribas Financial Markets Purchases New Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

ProShare Advisors LLC Buys 3,436 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

Jun 02, 2025
pulisher
May 31, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $354,000 Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

May 31, 2025
pulisher
May 30, 2025

Deutsche Bank AG Increases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

May 30, 2025
pulisher
May 29, 2025

Neffy provides needle-free relief to those with allergic reactions - KOIN.com

May 29, 2025
pulisher
May 28, 2025

ARS brings relief to your whole home - KOIN.com

May 28, 2025
pulisher
May 27, 2025

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

ARS Pharmaceuticals Leadership Takes Stage at 3 Major Investment Conferences This June - Stock Titan

May 27, 2025
pulisher
May 26, 2025

(SPRY) Trading Advice - news.stocktradersdaily.com

May 26, 2025
pulisher
May 25, 2025

D. E. Shaw & Co. Inc. Decreases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

May 25, 2025
pulisher
May 23, 2025

ARS Pharmaceuticals: neffy - WCIV

May 23, 2025
pulisher
May 22, 2025

Exploring US High Growth Tech Stocks In May 2025 - simplywall.st

May 22, 2025
pulisher
May 22, 2025

Brent Saunders Sells 120,000 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Expert Dr. Chase shares insights on Neffy for summer allergy season - KOKH

May 21, 2025
pulisher
May 19, 2025

FY2025 EPS Estimates for SPRY Cut by Cantor Fitzgerald - Defense World

May 19, 2025
pulisher
May 19, 2025

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by The Manufacturers Life Insurance Company - Defense World

May 19, 2025
pulisher
May 19, 2025

Needle-Free Emergency Epinephrine Now Available for Pediatric Patients - Dermatology Advisor

May 19, 2025
pulisher
May 19, 2025

Leerink Partnrs Has Bearish Outlook for SPRY Q2 Earnings - Defense World

May 19, 2025
pulisher
May 19, 2025

William Blair Brokers Lower Earnings Estimates for SPRY - Defense World

May 19, 2025
pulisher
May 18, 2025

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 10.8% – Still a Buy? - Defense World

May 18, 2025
pulisher
May 17, 2025

Price T Rowe Associates Inc. MD Reduces Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

May 17, 2025
pulisher
May 17, 2025

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2025 Earnings Call Transcript - MSN

May 17, 2025
pulisher
May 16, 2025

ARS Pharmaceuticals targets 80% commercial coverage for neffy in 2025 while expanding pediatric reach - MSN

May 16, 2025
pulisher
May 15, 2025

Ars Pharmaceuticals’ Neffy Launch Boosts Market Prospects - TipRanks

May 15, 2025
pulisher
May 15, 2025

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 15, 2025
pulisher
May 15, 2025

What You Need To Know About The ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analyst Downgrade Today - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Analysts Have Just Cut Their ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Revenue Estimates By 15% - simplywall.st

May 15, 2025
pulisher
May 15, 2025

ARS Pharmaceuticals (SPRY) Reports Strong Start with Neffy Launc - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Dimensional Fund Advisors LP Has $2.07 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

May 15, 2025
pulisher
May 15, 2025

ARS Pharmaceuticals Reports Strong Q1 2025 Performance - TipRanks

May 15, 2025
pulisher
May 14, 2025

SPRY Reports Q1 Revenue Surpassing Expectations, Preps for Key M - GuruFocus

May 14, 2025
pulisher
May 14, 2025

ARS Pharmaceuticals (SPRY) Reports Strong Start with Neffy Launch in Q1 2025 - GuruFocus

May 14, 2025
pulisher
May 14, 2025

ARS Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat

May 14, 2025
pulisher
May 14, 2025

ARS Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

Earnings call transcript: ARS Pharmaceuticals Q1 2025 revenue beats forecast - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Transcript : ARS Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

ARS Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Estimates at $8.0M, EPS Misses at -$0.35 - GuruFocus

May 14, 2025
pulisher
May 14, 2025

ARS Pharmaceuticals Q1 Operating Income USD -37.177 Million - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

ARS PHARMACEUTICALS Earnings Results: $SPRY Reports Quarterly Earnings - Nasdaq

May 14, 2025

Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Ars Pharmaceuticals Inc-Aktie (SPRY) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Karas Eric
Chief Commercial Officer
Jun 18 '25
Sale
16.00
15,000
240,000
7,696
$20.95
price up icon 1.40%
$36.00
price down icon 0.06%
$21.32
price down icon 0.15%
$99.07
price down icon 1.72%
$108.80
price up icon 2.21%
biotechnology ONC
$244.86
price up icon 1.07%
Kapitalisierung:     |  Volumen (24h):